Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting Kite says a two-year retrospective analysis of the commercial manufacturing and supply of its CAR T therapy, called axicabtagene ciloleucel (Yescarta), shows a high manufacturing success rate and a reliable turnaround time.
The data, presented at the virtual 47th European Society for Blood and Marrow Transplantation (EBMT) meeting in March 2021, provides the first real-world insights into axicabtagene ciloleucel (Axi-cel) manufacturing for European, Swiss, and Israeli adult patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), said the biopharma company.
Allo-HSCT Plus MAb Can Boost Survival in Patients With r/r B-ALL
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
GVHD Prophylaxis: Similar Outcomes With PTCy and ATG
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAN DIEGO, March 12, 2021 /PRNewswire/ Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b/2 study to prevent progression to severe organ toxicities in lymphoma subjects undergoing curative high-dose consolidation therapy with autologous hematopoietic cell transplantation (HDT-AHCT). Our investigators and Angiocrine are honored to be selected by EBMT to present at its annual meeting this March, commented Paul Finnegan, MD, Angiocrine CEO. We look forward to Dr. Caroline Mulroney s presentation of AB-205 s efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication.